Estrella Immunopharma nears completion of SPAC listing
The developer of T-cell cancer therapies is based in California, but says it ‘may be subject to risks’ due to its numerous China connections Key Takeaways: Estrella Immunopharma is nearing…
FAST NEWS: Legend Biotech Halts Trials for LB1901 CAR-T Therapy Drug
The latest: Legend Biotech Corp. (LEGN.US) announced that the Phase 1 clinical trial for its LB1901 drug has been put on hold. LB1901 is the company’s autologous chimeric antigen receptor…
RELATED ARTICLES
-
Stealthy eLong Power sneaks closer to U.S. listing
- China-U.S. IPOs take big step toward resumption with Cheche listing
-
Geely flexes deal-making muscle as Lotus Technology nears listing finish line
LOT.US
-
ZG Group and Aquila aim to score Hong Kong’s first SPAC merger success
7836.HK
- Sichuan Biokin chases Hong Kong listing after BSM drug deal
